Northwest Biotherapeutics (NWBO) Common Equity (2010 - 2026)

Northwest Biotherapeutics' Common Equity history runs 17 years deep, the most recent figure standing at -$50.5 million for Q1 2026.

• On a quarterly basis, Common Equity rose 49.19% year-over-year to -$50.5 million in Q1 2026; TTM through Mar 2026 was -$50.5 million, a 49.19% increase from a year earlier, with the FY2025 full-year figure at -$60.3 million, up 36.2% from the prior year.
• Common Equity improved to -$50.5 million in Q1 2026 per NWBO's latest filing, from -$60.3 million in the prior quarter.
• Across five years, Common Equity topped out at -$50.5 million in Q1 2026 and bottomed at -$128.1 million in Q4 2022.
• The 5-year median for Common Equity is -$80.1 million (2024), against an average of -$85.0 million.
• Across the five-year window, Common Equity jumped 73.8% in 2022 and sank 43.66% in 2024, its largest moves.
• Year by year, Common Equity stood at -$128.1 million in 2022, then jumped by 48.66% to -$65.8 million in 2023, then slumped by 43.66% to -$94.5 million in 2024, then jumped by 36.2% to -$60.3 million in 2025, then grew by 16.15% to -$50.5 million in 2026.
• Per Business Quant, the three latest NWBO Common Equity figures stand at -$50.5 million (Q1 2026), -$60.3 million (Q4 2025), and -$108.6 million (Q3 2025).